Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2009-08-24
2011-12-13
Peng, Bo (Department: 1648)
Chemistry: molecular biology and microbiology
Vector, per se
C435S455000, C435S456000, C424S093200
Reexamination Certificate
active
08076131
ABSTRACT:
The present invention provides new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, the invention provides new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.
REFERENCES:
patent: 5922315 (1999-07-01), Roy
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 6492169 (2002-12-01), Vogels et al.
patent: 6670188 (2003-12-01), Vogels et al.
patent: 6733993 (2004-05-01), Emini et al.
patent: 6913922 (2005-07-01), Bout et al.
patent: 7300657 (2007-11-01), Pau et al.
patent: 7387894 (2008-06-01), Pau et al.
patent: 7867764 (2011-01-01), Pau et al.
patent: 2003/0044421 (2003-03-01), Emini
patent: 99201545.3 (1999-05-01), None
patent: 0 978 566 (2000-02-01), None
patent: WO 96/26281 (1996-08-01), None
patent: WO 98/32842 (1998-07-01), None
patent: WO 98/50053 (1998-11-01), None
patent: WO 99/64582 (1999-12-01), None
patent: WO 00/03029 (2000-01-01), None
patent: WO 00/52186 (2000-09-01), None
patent: WO 00/60106 (2000-10-01), None
patent: WO 00/70071 (2000-11-01), None
patent: WO 01/02607 (2001-01-01), None
patent: WO 01/21201 (2001-03-01), None
patent: WO 02/22080 (2002-03-01), None
patent: WO 02/24730 (2002-03-01), None
patent: WO 02/053759 (2002-07-01), None
patent: WO 2004/028478 (2004-04-01), None
Rodrigues EG et al. “Single Immunizing Dose of Recombinant Adenovirus Efficiently Induces CD8+ T Cell-Mediated Protective Immunity Against Malarial” J. Immunology 158:1268-1274, 1997.
Bostic et al., Quantitative Analysis of Neutralizing Immune Response to Human Parvovirus B19 Using a Novel Reverse Transcriptase-Polymerase Chain Reaction-Based Assay, Journal of Infectious Diseases, 1999, pp. 619-626, vol. 179, Chicago, IL, US.
European Search Report, EP 03 78 0172, dated Dec. 6, 2007.
Hsu et al., “Immunogenicity of Recombinant Adenovirus-Respiratory Syncytial Virus Vaccines with Adenvirus Types 4, 5, and 7 Vectors in Dogs and a chimpanzee,” Journal of Infectious Diseases, Oct. 1, 1992, pp. 769-775, vol. 166, No. 4.
Kass-Eisler et al., “Circumventing the immune response to adenovirus-mediated gene therapy,” Gene Therapy, Feb. 1, 1996, pp. 154-162, vol. 2, No. 3.
Klein et al., Accurate estimation of transduction efficiency necessitates a multiplex real-time PCR, Gene Therapy, 2000, pp. 458-463, vol. 7.
Lubeck et al., “Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus,” Proc. Natl. Acad. Sci. USA, 1989, pp. 6763-6767, vol. 86, No. 17.
Mack et al., “Circumvention of Anti-Adenovirus Neutralizing Immunity by Administration of an Adenoviral Vector of an Alternate Serotype,” Human Gene Therapy, 1997, pp. 99-109, vol. 8, No. 1.
Mastrangeli et al., “‘Sero-Switch’ Adenovirus-Mediated in Vivo Gene Transfer: Circumvention of Anti-Adenovirus Humoral Immune Defenses Against Repeat Adenovirus Vector Administration by Changing the Adenovirus Serotype,” Human Gene Therapy, 1996. pp. 79-87, vol. 7, No. 1.
Moffatt et al., “Circumvention of Vector-Specific Neutralizing Antibody Response by Alternating Use of Human and Non-Human Adenoviruses: Implications in Gene Therapy,” Virology, Jun. 30, 2000, pp. 159-167, vol. 272, No. 1.
Natuk et al., “Adenovirus Vectored Vaccines,” Developments in Biological Standardization, 1994, pp. 71-77, vol. 82.
Natuk et al., “Adenovirus—human deficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model,” Proc. Natl. Acad. Sci. USA, Aug. 1992, pp. 7777-7781, vol. 89, No. 16.
Natuk et al., “Immunogenicity of Recombinant Human Adenovirus—Human Immunodeficiency Virus Vaccines in Chimpanzees,” AIDS Research and Human Retroviruses, 1993, pp. 395-404, vol. 9, No. 5.
Nishimura et al., Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies, Journal of Virology, Mar. 2002, pp. 2123-2130, vol. 76, No. 5.
Parks et al., “Use of a helper-dependent adenoviral vectors of alternative serotype permits repeat vector administration,” Gene Therapy, Sep. 1999, pp. 1565-1573, vol. 6, No. 1.
PCT International Preliminary Examination Report, PCT/EP03/50748, dated Feb. 14, 2005.
PCT International Search Report, PCT/EP03/50748, dated Sep. 27, 2004.
Rodrigues et al., Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria, J. Immunol., Feb. 1, 1997, pp. 1268-1274, vol. 158, No. 3.
Roy et al., “Circumvention of Immunity to the Adenovirus Major Coat Protein Hexon,” Journal of Virology, Aug. 1998, pp. 6875-6879, vol. 72, No. 8.
Schroter et al., Quantitative Detection of Hepatitis C Virus RNA by Light Cycler PCR and Comparison with Two Different PCR Assays, Journal of Clinical Microbiology, Feb. 2001, pp. 765-768, vol. 39, No. 2.
Spenlehauer et al., A Luciferase-Reporter Gene-Expressing T-Cell Line Facilitates Neutralization and Drug-Sensitivity Assays That Use Either R5 or X4 Strains of Human Immunodeficiency Virus Type 1, Virology, 2001, pp. 292-300, vol. 280.
Sprangers et al., Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors, Journal of Clinical Microbiology, Nov. 2003, pp. 5046-5052, vol. 41, No. 11.
Tetteh et al., Progress and challenges towards the development of malaria vaccines, Biogruds, 2007, pp. 357-373, vol. 21, No. 6.
Vogels et al., Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity, Journal of Virology, Aug. 2003, pp. 8263-8271, vol. 77, No. 15.
Stallwood et al., Neutralisation of adenovirus infectivity by ascetic fluid from ovarian cancer patients, Gene Ther., Apr. 2000, pp. 637-643, vol. 7, No. 8.
U.S. Appl. No. 11/018,669, filed Dec. 20, 2004, Vogels et al., Gene Delivery Vectors Provided With a Tissue Tropism for Smooth Muscle Cells, and/or Endothelial Cells.
U.S. Appl. No. 11/105,725, filed Apr. 14, 2005, Havenga et al., New Settings for Recombinant Adenoviral-Based Vaccines.
U.S. Appl. No. 11/140,418, filed May 27, 2005, Vogels et al., Serotype of Adenovirus and Uses Thereof.
U.S. Appl. No. 11/207,626, filed Aug. 18, 2005, Havenga et al., Chimaeric Adenoviruses.
U.S. Appl. No. 11/384,850, filed Mar. 20, 2006, Havenga et al., Packaging Cells for Recombinant Adenovirus.
U.S. Appl. No. 11/586,316, filed Oct. 25, 2006, Bout et al., Serotypes of Adenovirus and Uses Thereof.
U.S. Appl. No. 11/665,276, filed Apr. 11, 2007, Havenga et al., Improved Adenoviral Vectors and Uses Thereof.
U.S. Appl. No. 11/665,393, filed Apr. 13, 2007, Pau et al., Malaria Prime/Boost Vaccines.
U.S. Appl. No. 11/667,975, filed May 16, 2007, Havenga et al., Multivalent Vaccines Comprising Recombinant Viral Vectors.
U.S. Appl. No. 11/786,409, filed Apr. 11, 2007, Vogels et al., Complementing Cell Lines.
U.S. Appl. No. 11/800,871, filed May 7, 2007, Vogels et al., Means and Methods for the Production fo Adenovirus Vectors.
U.S. Appl. No. 11/809,697, filed Jun. 1, 2007, Hateboer et al., Recombinant Protein Production in a Human Cell.
U.S. Appl. No. 11/879,422, filed Jul. 16, 2007, Marzio et al., Production of Viruses, Viral Isolates and Vaccines.
U.S. Appl. No. 11/899,572, filed Sep. 5, 2007, Vogels et al., Stable Adenoviral Vectors and Methods for Propagation Thereof.
U.S. Appl. No. 11/975,396, filed Oct. 18, 2007, Pau et al., Recombinant Viral-Based Malaria Vaccines.
U.S. Appl. No. 11/978,043, filed Oct. 25, 2007, Vogels et al., New Settings for Recombinant Adenoviral-Based Vaccines.
U.S. Appl. No. 11/980,222, filed Oct. 29, 2007, Bout et al., Serotypes of Adenovirus and
Havenga Menzo Jans Emco
Holterman Lennart
Kostense Stefan
Pau Maria Grazia
Sprangers Mieke Caroline
Crucell Holland B.V.
Peng Bo
TraskBritt P.C.
LandOfFree
Settings for recombinant adenoviral-based vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Settings for recombinant adenoviral-based vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Settings for recombinant adenoviral-based vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4265201